acute myocardial infarction

     

Select            
Trial Studied trt Control trt patientstagsROB Trial resultAll cause deathreinfarction

angiotensin-Converting Enzyme Inhibitors

captopril
ISIS-4, 1995   captoprilplaceboLow risk of bias - -6%
CCS-1, 1995   captoprilplaceboLow risk of bias -
French, 1999     captoprilplaceboLow risk of bias -
CATS, 1996     captoprilplaceboLow risk of bias -
ECCE, 1997   captoprilplaceboLow risk of bias -
Sharpe, 1991     captoprilplaceboLow risk of bias -
Ray, 1993     captoprilplaceboLow risk of bias -
Nabel, 1991   captoprilplaceboLow risk of bias -
Bussmann, 1992   captoprilplaceboLow risk of bias -
Di Pasquale, 1994   captoprilplaceboLow risk of bias -
Di Pasquale, 1997   captoprilplaceboLow risk of bias -
Galcera, 1993   captoprilplaceboLow risk of bias -
Hargreaves, 1992   captoprilplaceboLow risk of bias -
SAVE, 1992   captoprilplaceboLow risk of bias -
Pfeffer, 1988   captoprilplaceboLow risk of bias -
Sogaard, 1994   captoprilplaceboLow risk of bias -
Sharpe, 1988     captoprilplaceboLow risk of bias -
Mortarino, 1990   captoprilplaceboLow risk of bias -
PRACTICAL (captopril), 1994   captopril or enalaprilplaceboLow risk of bias -
enalapril
CONSENSUS 2, 1992   enalaprilplaceboLow risk of bias -
Schulman, 1995     enalaprilplaceboLow risk of bias -
fosinopril
FAMIS, 1998     fosinoprilplaceboLow risk of bias -
lisinopril
GISSI 3, 1994   lisinoprilplaceboRisk of bias -
ramipril
Wagner, 2002   ramiprilplaceboLow risk of bias -
AIRE, 1993   ramiprilplaceboLow risk of bias -
trandolapril
TRACE, 1995     trandolaprilplaceboLow risk of bias -
zofenopril
SMILE, 1995     zofenoprilplaceboLow risk of bias suggesting

angiotensin-receptor blockers

losartan
OPTIMAAL, 2002     LosartanCaptoprilLow risk of bias suggesting
valsartan
VALIANT (valsartan+capropril), 2003     Valsartan+ACE inhibitor ACE inhibitor onlyLow risk of bias negative
VALIANT (valsartan alone), 2003     ValsartanCaptoprilLow risk of bias negative

antiarrythmic drugs

not classified
Koster and Dunning, 1985   IM lidocaine (without infusion)controlRisk of bias negative-8%
Bennett, 1970   IV lidocaine infusioncontrolRisk of bias negative151%
Pitt, 1971   IV lidocaine infusioncontrolRisk of bias negative27%
Darby, 1972   IV lidocaine infusioncontrolRisk of bias negative36%
Sandlar   IM lidocaine (without infusion)placeboLow risk of bias negative
Singh and Kocot, 1976   IM lidocaine (without infusion)placeboLow risk of bias negative
Lie (IM), 1978   IM lidocaine (without infusion)placeboLow risk of bias negative
Dunn, 1985     IM lidocaine (without infusion)placeboLow risk of bias negative183%
Kostuk and Beanlands   IV lidocaine infusionplaceboLow risk of bias negative
Baker, 1971   IV lidocaine infusionplaceboLow risk of bias negative+Infini%
Chopra, 1971   IV lidocaine infusionplaceboLow risk of bias negative121%
O   IV lidocaine infusionplaceboLow risk of bias negative102%
Lie (IV), 1974   IV lidocaine infusionplaceboLow risk of bias negative-21%
Wyse, 1988   IV lidocaine infusionplaceboLow risk of bias negative195%
dofetilide
DIAMOND MI, 1997   dofetilideplaceboLow risk of bias -
magnesium
ISIS-4, 1995   magnesiumcontrolsuggesting 6%
Wu, 1992   magnesiumcontrolLow risk of bias suggesting-66%
Zhu, 2002   magnesiumcontrolsuggesting-34%
Abraham, 1987   magnesiumplaceboLow risk of bias negative-4%
MAGIC, 2000      NCTmagnesiumplaceboLow risk of bias negative0%
Bhargava, 1995     magnesiumplaceboLow risk of bias suggesting-5%
Ceremuzynski, 1989   magnesiumplacebosuggesting-69%
Chen, 1991   magnesiumplacebosuggesting
Feldstedt, 1991     magnesiumplaceboLow risk of bias negative23%
Gyamlani, 2000   magnesiumplaceboLow risk of bias suggesting-80%
Ising, 1990   magnesiumplacebo -
Morton, 1984   magnesiumplaceboLow risk of bias negative -55%
Nakashima, 2004     magnesiumplaceboLow risk of bias negative-66%
Parikka, 1990     magnesiumplaceboLow risk of bias negative
Raghu, 1999     magnesiumplaceboLow risk of bias suggesting-64%
Rasmussen, 1986   magnesiumplaceboLow risk of bias negative-62%
Santoro, 2000   magnesiumplaceboLow risk of bias negative-100%
Shechter, 1990     magnesiumplaceboLow risk of bias suggesting-88%
Shechter, 1991   magnesiumplaceboLow risk of bias negative-40%
Shechter, 1995     magnesiumplaceboLow risk of bias suggesting-76%
Singh, 1990   magnesiumplaceboLow risk of bias suggesting-45%
Smith, 1986   magnesiumplaceboLow risk of bias negative-71%
Thogersen, 1995     magnesiumplaceboLow risk of bias negative-53%
Urek, 1996   magnesiumplaceboLow risk of bias negative+Infini%
Woods, 1992       magnesiumplaceboLow risk of bias suggesting -24%
moricizine
CAST II (early treatment), 1992   moricizineplaceboLow risk of bias -

anticoagulant

not classified
Sixty Plus reinfarction Study, 1980   any anticoagulantplaceboLow risk of bias -
German-Austrian Study Group (oac vs pbo), 1980   phenprocoumonplaceboLow risk of bias negative14%
EPSIM, 1982   any anticoagulantaspirinnegative-10%
German-Austrian Study Group (oac vs asp), 1980   phenprocoumonaspirinLow risk of bias negative 43%
coumadin
ASPECT-2 (coumadin+ASA vs ASA), 2002     coumadincontrol (on top of aspirin)negative -42%
ASPECT, 1994   coumadinplaceboLow risk of bias suggesting -10%
ASPECT-2 (coumadin alone), 2002     coumadinaspirinsuggesting-72%
warfarin
APRICOT-2, 2002     warfarincontrol (on top of aspirin)suggesting+Infini%
Zibaeenezhad, 2004   warfarincontrol (on top of aspirin)negative -67%
WARIS, 1999   warfarincontrol (on top of aspirin)Low risk of bias -
CHAMP, 2002     warfarincontrol (on top of aspirin)negative 2%
CARS (warafrin 3mg), 1997     warfarincontrol (on top of aspirin)Low risk of bias suggesting-27%
LoWASA, 2004     warfarincontrol (on top of aspirin)Risk of bias suggesting -5%
CARS (warfarin 1mg), 1997     warfarincontrol (on top of aspirin)Low risk of bias negative 3%
WARIS II (warfarin+ASA), 2002     warfarincontrol (on top of aspirin)suggesting -2%
Williams, 1997     warfarinplacebo (on top of aspirin)Low risk of bias suggesting-100%
WARIS II (warfarin alone), 2002     warfarinaspirinsuggesting 3%

antiplatelets drug

not classified
Jones, 1987   dazoxibencontrolnegative
GRAND, 1987   GR3219Bcontrolnegative
Gent-AMI, 1968   misc.controlnegative
Johannessen, 1989     misc.controlnegative
French, 1993     flurbiprofenplaceboLow risk of bias suggesting
aspirin
Huddinge, 1988     aspirincontrolnegative
Frankfurt, 1976   aspirincontrolnegative
Dutch-aspirin, 1990     aspirinplaceboLow risk of bias negative
ISIS-pilot, 1987     aspirinplaceboLow risk of bias negative
ISIS-2, 1988   aspirinplaceboLow risk of bias suggesting
APRICOT, 1993   aspirinplaceboLow risk of bias suggesting
clopidogrel
COMMIT, 2005      NCTclopidogrelplaceboLow risk of bias suggesting
CLARITY-TIMI 28, 2005   clopidogrelplaceboLow risk of bias -
elinogrel
ERASE-MI, 2009     elinogrelplaceboLow risk of bias negative
sulfinpyrazone
Dutch sulphinpyrazone, 1986   sulfinpyrazonecontrolnegative
Wilcox, 1980   sulfinpyrazoneplacebonegative
Louvain sulphinpyrazone, 1983   sulfinpyrazoneplaceboLow risk of bias negative
ticlopidine
Knudsen-A, 1985   ticlopidinecontrolnegative

antithrombotics

not classified
Sixty Plus reinfarction Study, 1980   any anticoagulantplaceboLow risk of bias -
German-Austrian Study Group (oac vs pbo), 1980   phenprocoumonplaceboLow risk of bias negative14%
EPSIM, 1982   any anticoagulantaspirinnegative-10%
German-Austrian Study Group (oac vs asp), 1980   phenprocoumonaspirinLow risk of bias negative 43%
argatroban
ARGAMI-2, 1998       Argatrobanheparin -
bivalirudin
HERO, 1997     bivalirudinheparinLow risk of bias suggesting
coumadin
ASPECT-2 (coumadin+ASA vs ASA), 2002     coumadincontrol (on top of aspirin)negative -42%
ASPECT, 1994   coumadinplaceboLow risk of bias suggesting -10%
ASPECT-2 (coumadin alone), 2002     coumadinaspirinsuggesting-72%
dalteparin
FRAMI, 1997     Dalteparinplacebo -
BIOMACS II, 1999     DalteparinplaceboLow risk of bias -
ASSENT Plus, 2003     DalteparinUFHnegative
enoxaparin
AMI-SK, 2002     EnoxaparinplaceboLow risk of bias -
ASSENT 3, 2001     EnoxaparinUFHsuggesting
HART II, 2001     EnoxaparinUFHnegative
Baird, 2002     EnoxaparinUFHnegative
ENTIRE-TIMI 2, 2002     EnoxaparinUFHsuggesting
ASSENT 3 Plus, 2003     EnoxaparinUFHnegative
fondaparinux
MICHELANGELO OASIS-6, 2006      NCTfondaparinuxplaceboLow risk of bias suggesting-32%
hirudin
HIT-4, 1999     HirudinheparinLow risk of bias -
TIMI 9B, 1996     HirudinheparinRisk of bias -
reviparin
CREATE, 2005     ReviparinplaceboLow risk of bias -
UFH
ISIS-2 Pilot, 1987     UFHno heparinnegative-81%
DUCCS, 1994   UFHno heparinnegative114%
ECSG, 1992     UFHplaceboLow risk of bias negative-1%
OSIRIS, 1992   UFHplaceboLow risk of bias negative100%
warfarin
APRICOT-2, 2002     warfarincontrol (on top of aspirin)suggesting+Infini%
Zibaeenezhad, 2004   warfarincontrol (on top of aspirin)negative -67%
WARIS, 1999   warfarincontrol (on top of aspirin)Low risk of bias -
CHAMP, 2002     warfarincontrol (on top of aspirin)negative 2%
CARS (warafrin 3mg), 1997     warfarincontrol (on top of aspirin)Low risk of bias suggesting-27%
LoWASA, 2004     warfarincontrol (on top of aspirin)Risk of bias suggesting -5%
CARS (warfarin 1mg), 1997     warfarincontrol (on top of aspirin)Low risk of bias negative 3%
WARIS II (warfarin+ASA), 2002     warfarincontrol (on top of aspirin)suggesting -2%
Williams, 1997     warfarinplacebo (on top of aspirin)Low risk of bias suggesting-100%
WARIS II (warfarin alone), 2002     warfarinaspirinsuggesting 3%

beta-blockers

not classified
Julian , 1982   Sotalol placeboLow risk of bias